4 Search Results

q=Grants

Search Again


James Dai , PhD

Email: jdai@fredhutch.org

Phone: (206) 667-6364

James Dai’s Lab works in statistical genetics and genomics, design and analysis of randomized clinical trials, statistical methods for high-dimensional feature selection and prediction, gene-treatment interaction, mediation and instrumental variables regression. Methodologically, his lab is also interested in cancer genomics topics, for example integrative genomic analyses and intra-tumor heterogeneity. The overarching scientific interest is to discover and validate and genomic markers that drive cancer etiology, predict cancer prognosis and treatment efficacy.

View Bio

Jeff Delrow , PhD

Email: jdelrow@fredhutch.org

Phone: (206) 667-2763

Dr. Delrow is the director of the bioinformatics resource at Fred Hutch. His primary role is to support researchers who need assistance with the analysis of genomics and proteomics data.

View Bio

Amy Paguirigan , PhD

Email: apaguiri@fredhutch.org

Phone: (206) 667-4352

The focus of my research has been the integration of emerging technologies to address clinically relevant questions in cancer biology. My focus is on the interface between clinical molecular biology, bioinformatics and biotechnology, in aiming to bridge the gaps to bring novel approaches in both the biotechnological and informatics realms to clinical molecular biology to study the role of clonal diversity in cancer therapy.

View Bio

Takuma Uo , Ph.D.

Email: tuo@uw.edu

Phone: 206-897-5463

Age is the most common risk factor for prostate cancer, with the rapid rise in its incidence after age 50. As a member of the prostate cancer research group in Division of Gerontology and Geriatric Medicine, Dr. Uo is focused on understanding molecular logics behind adaptive resistance of prostate cancer cells to the most forefront androgen-targeted therapies. Specifically, his research program examines the cell autonomous and nonautonomous mechanisms that enable prostate cancer progression, including the constitutively-active isoforms of androgen receptor, the metabolic rewiring, and the extracellular fuel supply from tumor microenvironment and adipose tissues. He harnesses in-depth knowledge and advanced technologies of molecular, cellular, chemical, synthetic, and computational biology to help develop next-generation of therapeutics to improve patient survival.

View Bio